Published online March 1, 2006
PEDIATRICS Vol. 117 No. 3 March 2006, pp. S1-S8 (doi:10.1542/peds.2005-0620B)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giacoia, G. P.
Right arrow Articles by Mattison, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giacoia, G. P.
Right arrow Articles by Mattison, D. R.
Related Collections
Right arrow Premature & Newborn

SUPPLEMENT ARTICLE

The Newborn Drug Development Initiative

George P. Giacoia, MDa, Debra L. Birenbaum, MDb, Hari Cheryl Sachs, MDb and Donald R. Mattison, MDa

a Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
b Division of Pediatric Drug Development, Office of Counter-Terrorism and Pediatric Drug Development, Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services, Silver Spring, Maryland

The Best Pharmaceuticals for Children Act (BPCA; Pub L 107-109) was enacted in January 2002 and will sunset in October 2007. The BPCA established processes for studying off-patent and on-patent drugs that are used in pediatric population. Although some drugs have been successfully developed for the neonate (eg, surfactant, nitric oxide), drug development for the youngest, least mature, and most vulnerable pediatric patients is generally lacking. Most drugs are empirically administered to newborns once efficacy has been demonstrated in adults and usefulness is suspected or demonstrated in the older pediatric population. Unfortunately, this process undermines the ability to perform the appropriate studies necessary to demonstrate a drug's short- and long-term safety and efficacy and establish appropriate dosing in neonates. The Newborn Drug Development Initiative Workshop I (held March 29–30, 2004) specifically addressed scientific, clinical, and ethical concerns in the development of trials of pediatric therapeutic agents for neonates. Implementation of the BPCA for all pediatric populations will foster collaboration among federal agencies and academic institutions on scientific investigation, clinical-study design, and consideration of the weight of evidence and address ethical issues related to the performance of drug studies.

Key Words: clinical research/trials • neonatology • clinical-trial design

Abbreviations: BPCA—Best Pharmaceuticals for Children Act • FDA—Food and Drug Administration • NIH—National Institutes of Health • NICHD—National Institute of Child Health and Human Development • NDDI—Newborn Drug Development Initiative

Accepted Oct 17, 2005.




This article has been cited by other articles:


Home page
 Arch Pediatr Adolesc MedHome page
P. Taylor-Zapata and D. R. Mattison
Making Progress for How Medicines Are Used in Children
Arch Pediatr Adolesc Med, September 1, 2007; 161(9): 916 - 916.
[Full Text] [PDF]